Felix Gold secures Alaskan permit for bulk sampling
Felix Gold (ASX:FXG) marked a milestone following the receipt of a bulk sampling permit from the Alaska Department of Natural Resources.

TV presenter and finance editor at Grafa, with a Master’s in Commerce from UWA and diverse industry experience in finance, insurance, and media.
Felix Gold (ASX:FXG) marked a milestone following the receipt of a bulk sampling permit from the Alaska Department of Natural Resources.
Minerals 260 (ASX:MI6) secured FIRB approval for Franco-Nevada mortgage arrangements, unlocking a $95 million payment.
Abivax (NASDAQ:ABVX) today announced its full-year 2025 financial results and provided a comprehensive corporate update, underscored by a significantly strengthened capital structure and steady clinical progress.
Digital asset investment products recorded $230 million in net inflows for the week ending 21 March, according to a weekly report released by CoinShares.
HomesToLife (NASDAQ:HTLM) today announced its audited financial results for the fiscal year ended December 31, 2025, reporting a year of record profitability and sustained international expansion.
Talphera (NASDAQ:TLPH) today reported financial results for the fourth quarter and full year ended December 31, 2025, detailing the fiscal costs of its ongoing transition into a specialized developer of hospital-based therapies.
Ondas Holdings (NASDAQ:ONDS) today reported a landmark financial performance for the fourth quarter and full year ended December 31, 2025, marking its transition from an early-stage innovator to a high-scale industrial technology leader.
Bausch + Lomb (NYSE:BLCO) today unveiled positive topline results from its pivotal 24-month U.S. clinical trial of the ELIOS System, an innovative, implant-free procedure designed to treat elevated intraocular pressure (IOP) in patients with open-angle glaucoma.
Ennis (NYSE:EBF), a premier manufacturer of business forms and essential printed products, announced today that its Board of Directors has declared a quarterly cash dividend of $0.25 per share on the company’s common stock.
Evotec (NASDAQ:EVO) announced today that its Seattle-based subsidiary, Just - Evotec Biologics, has been selected by the Biomedical Advanced Research and Development Authority (BARDA) to optimize the manufacturing of medical countermeasures against life-threatening filoviruses.
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy